Shopping Cart
Remove All
Your shopping cart is currently empty
Anti-DR5/TRAIL R2 Antibody (9F7) is a Mouse antibody targeting DR5/TRAIL R2. Anti-DR5/TRAIL R2 Antibody (9F7) can be used in ELISA,ICC/IF.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 100 μL | $199 | 7-10 days | 7-10 days |
| Description | Anti-DR5/TRAIL R2 Antibody (9F7) is a Mouse antibody targeting DR5/TRAIL R2. Anti-DR5/TRAIL R2 Antibody (9F7) can be used in ELISA,ICC/IF. |
| Synonyms | ZTNFR9, tumor necrosis factor receptor superfamily, member 10b, TRICKB, TRICK2B, TRICK2A, TRICK2, TRAIL-R2, TRAILR2, KILLER/DR5, KILLER, DR5, CD262 |
| Ig Type | Mouse IgG1 |
| Clone | 9F7 |
| Reactivity | Human |
| Specificity | Human DR5/TRAIL R2 |
| Verified Activity | Immunofluorescence staining of TNFRSF10B in HCT116 cells. Cells were fixed with 4% PFA, permeabilzed with 0.1% Triton X-100 in PBS,blocked with 10% serum, and incubated with mouse anti-Human TNFRSF10B monoclonal antibody (dilution ratio 1:60) at 4°C overnight. Then cells were stained with the Alexa Fluor®488-conjugated Goat Anti-mouse IgG secondary antibody (green) and counterstained with DAPI (blue).Positive staining was localized to Cytoplasm. |
| Application | |
| Recommended Dose | ELISA: 1:1000-1:2000; ICC-IF: 1:20-1:100 |
| Antibody Type | Monoclonal |
| Host Species | Mouse |
| Construction | This product is a recombinant monoclonal antibody expressed from HEK293 cells. |
| Purification | Protein A |
| Appearance | Liquid |
| Formulation | 0.2 μm filtered solution in PBS |
| Research Background | Tumor necrosis factor receptor superfamily, member 10b, official symbol TNFRSF10B, also known as Death receptor 5, CD262, TNF-related apoptosis-inducing ligand receptor 2 (TRAIL R2), is a member of the TNF-receptor superfamily, and contains an intracellular death domain. This receptor can be activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL/APO-2L), and transduces an apoptosis signal. Studies with FADD-deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by this protein. TRAIL R2/CD262/TNFRSF10B was purified independently as the only receptor for TRAIL detectable on the surface of two different human cell lines that undergo apoptosis upon stimulation with TRAIL. TRAIL R2/CD262/TNFRSF10B contains two extracellular cysteine-rich repeats, typical for TNF receptor (TNFR) family members, and a cytoplasmic death domain. TRAIL R2/CD262/TNFRSF10B mediates apoptosis via the intracellular adaptor molecule FADD/MORT1. TRAIL receptors can signal both death and gene transcription, functions reminiscent of those of TNFR1 and TRAMP, two other members of the death receptor family. Defects in TRAIL R2/CD262/TNFRSF10B may be a cause of head and neck squamous cell carcinomas (HNSCC) also known as squamous cell carcinoma of the head and neck.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy |
| Conjucates | Unconjugated |
| Immunogen | Recombinant Protein: Human DR5/TRAIL R2 Protein (TMPY-01185) |
| Antigen Species | Human |
| Biology Area | Cancer Drug Targets |
| Stability & Storage | Store at 2°C-8°C for 1 month. Store at -20°C or -80°C for 12 months. Avoid repeated freeze-thaw cycles. Preservative-Free. |
| Transport | Shipping with blue ice. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.